Bristol Myers Squibb stock $BMY (-3,31 %) rose 6.5% on Monday after the company announced positive topline results from two separate Phase 3 clinical trials. These trials evaluated targeted therapies for neuroendocrine tumors and idiopathic pulmonary fibrosis.
Best regards 🌊

